News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
72,088 Results
Type
Article (836)
Company Profile (6)
Press Release (71246)
Section
Business (23519)
Career Advice (15)
Deals (5811)
Drug Development (10265)
Employer Resources (3)
FDA (1192)
Job Trends (1190)
News (39619)
Policy (2660)
Tag
Academia (126)
Allergies (5)
Alliances (3452)
ALS (4)
Alzheimer's disease (85)
Antibody-drug conjugate (ADC) (1)
Approvals (1212)
Artificial intelligence (6)
Autoimmune disease (4)
Bankruptcy (48)
Best Places to Work (1133)
Biosimilars (1)
Biotechnology (3)
Bladder cancer (9)
Brain cancer (1)
Breast cancer (23)
Cancer (186)
Cardiovascular disease (17)
Career advice (15)
CAR-T (7)
Cell therapy (25)
Cervical cancer (1)
Clinical research (8627)
Collaboration (41)
Compensation (74)
COVID-19 (160)
C-suite (14)
Cystic fibrosis (8)
Data (240)
Depression (3)
Diabetes (15)
Diagnostics (494)
Digital health (1)
Drug discovery (2)
Drug pricing (1)
Duchenne muscular dystrophy (8)
Earnings (15526)
Employer resources (2)
Events (13394)
Executive appointments (35)
FDA (1312)
Frontotemporal dementia (1)
Funding (31)
Gene editing (1)
Gene therapy (3)
GLP-1 (19)
Government (243)
Guidances (41)
Healthcare (1963)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (13)
Indications (3)
Infectious disease (171)
Inflammatory bowel disease (15)
Influenza (8)
Intellectual property (8)
Interviews (2)
IPO (4288)
Job creations (120)
Job search strategy (14)
Layoffs (10)
Legal (670)
Liver cancer (5)
Lung cancer (31)
Lymphoma (12)
Management (1)
Manufacturing (7)
MASH (12)
Medical device (1393)
Medtech (1393)
Mergers & acquisitions (1604)
Metabolic disorders (45)
Multiple sclerosis (6)
Neurodegenerative disease (4)
Neuropsychiatric disorders (1)
Neuroscience (119)
NextGen: Class of 2025 (448)
Non-profit (213)
Obesity (18)
Opinion (2)
Ovarian cancer (6)
Pain (1)
Pancreatic cancer (7)
Parkinson's disease (9)
Partnered (1)
Patents (25)
Patient recruitment (5)
Peanut (3)
People (4625)
Phase I (2485)
Phase II (3892)
Phase III (2938)
Pipeline (236)
Policy (1)
Postmarket research (308)
Preclinical (999)
Press Release (1)
Prostate cancer (9)
Radiopharmaceuticals (36)
Rare diseases (21)
Real estate (239)
Recruiting (2)
Regulatory (1885)
Research institute (97)
RSV (2)
Schizophrenia (7)
Series A (3)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Spinal muscular atrophy (16)
Startups (166)
Supply chain (3)
Tariffs (1)
Vaccines (25)
Weight loss (3)
Women's health (1)
Date
Today (10)
Last 7 days (121)
Last 30 days (285)
Last 365 days (3276)
2025 (1174)
2024 (3760)
2023 (4566)
2022 (7007)
2021 (7260)
2020 (9877)
2019 (4751)
2018 (3469)
2017 (3569)
2016 (2699)
2015 (3891)
2014 (2381)
2013 (1398)
2012 (1747)
2011 (1835)
2010 (1435)
Location
Africa (21)
Alabama (16)
Arizona (7)
Asia (4170)
Australia (501)
California (736)
Canada (138)
China (38)
Colorado (19)
Connecticut (34)
Delaware (28)
Europe (7016)
Florida (104)
Georgia (12)
Illinois (49)
India (1)
Indiana (20)
Japan (13)
Kansas (11)
Louisiana (3)
Maine (2)
Maryland (59)
Massachusetts (516)
Michigan (17)
Minnesota (37)
Missouri (2)
Montana (1)
Nebraska (1)
Nevada (5)
New Hampshire (8)
New Jersey (228)
New York (283)
North Carolina (130)
Northern California (315)
Ohio (6)
Pennsylvania (131)
Rhode Island (1)
South America (53)
Southern California (321)
Tennessee (5)
Texas (125)
United States (2618)
Utah (12)
Virginia (49)
Washington D.C. (1)
Washington State (31)
Wisconsin (2)
72,088 Results for "212".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
April 8, 2025
·
7 min read
Press Releases
BioDlink Applauds Junshi Biosciences on IND Approval of Bispecific ADC Candidate JS212
May 9, 2025
·
1 min read
Press Releases
Telix Adds Lead-212 Isotope Production Capability
March 13, 2025
·
6 min read
Press Releases
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
February 12, 2025
·
6 min read
Layoffs
Rallybio Downsizes by 40% After Dropping Lead Asset
The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage pharmacokinetic findings in a rare bleeding disorder.
May 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
November 21, 2024
·
6 min read
Press Releases
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
January 22, 2025
·
7 min read
Drug Development
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024.
June 4, 2024
·
7 min read
Press Releases
Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia
January 9, 2025
·
5 min read
Business
ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States
PharmaLogic Holdings Corp. and ARTBIO today announce a manufacturing and supply agreement for ARTBIO’s lead-212 (212Pb) based radiopharmaceutical candidate, AB001, for the treatment of prostate cancer.
January 12, 2024
·
3 min read
1 of 7,209
Next
